Intramolecular Imaging with ICG (PRIME)

Intramolecular Imaging with ICG (PRIME)

Brief description of study

The purpose of this protocol is to monitor the rate of recurrence in patients who undergo cancer surgery. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. The high rates of recurrence suggest that surgeons are unable to completely detect and remove primary tumor nodules in a satisfactory manner as well as lingering metastases in sentinel lymph nodes. There is some data to suggest that near infrared imaging can can improve on negative margins. Patients with a diagnosis of any resectable solid tumor, including but not limited to lung nodule, breast, kidney, parathyroid, mediastinal, skin mass, soft tissue, prostate, stomach pleural, head and neck, and are at risk for local recurrence as determined by pre-operative assessment at an office in the University of Pennsylvania Heath System will be included.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Solid Tumors
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 09 Mar 2024. Study ID: 844554
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center